Form 4: Astria Therapeutics Director Disposes Shares Post-Merger

Jonathan Violin, a director of Astria Therapeutics, Inc., reported the disposition of all his common stock and stock options following the company's merger with BioCryst Pharmaceuticals, Inc.

Summary

• Jonathan Violin, a director of Astria Therapeutics, Inc. (ATXS), reported the disposition of all his beneficial ownership in the company.
• This transaction occurred on January 23, 2026, as a result of Astria Therapeutics merging with Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.
• Astria Therapeutics became a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc. (BioCryst).
• Each share of Astria Therapeutics common stock was converted into 0.59 shares of BioCryst common stock and $8.55 in cash, subject to withholding taxes.
• In-the-money stock options (exercise price less than $13.00) were fully vested, exercisable, and canceled for a cash payment based on the difference between $13.00 and the exercise price.
• Out-of-the-money stock options (exercise price equal to or greater than $13.00) were canceled for no consideration and are not reported in this filing.
• Mr. Violin disposed of 263,321 shares of common stock and a total of 77,249 stock options with various exercise prices.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, providing a defined exit for shareholders with a mix of cash and stock. While out-of-the-money options were canceled, the overall event represents a positive resolution for the company's equity holders, indicating a successful corporate transaction.

Positives

• The merger provided a clear exit strategy for Astria Therapeutics shareholders, converting their shares into a combination of BioCryst stock and cash.
• In-the-money stock options were cashed out, providing value to option holders.

Negatives

• Out-of-the-money stock options were canceled for no consideration, resulting in a loss of potential value for those option holders.
• Astria Therapeutics ceased to exist as an independent publicly traded entity.

Risks

• Shareholders of Astria Therapeutics are now exposed to the risks associated with BioCryst Pharmaceuticals, Inc.
• The cash component of the merger consideration is subject to withholding taxes.
• Fractional shares of BioCryst common stock were converted to cash, potentially limiting full equity participation for some shareholders.

Future Outlook

The filing primarily reports a past transaction (merger completion) and does not provide forward-looking statements or guidance for the combined entity. The future outlook for former Astria Therapeutics shareholders is now tied to BioCryst Pharmaceuticals, Inc.

Management Comments

• Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ('BioCryst'), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the 'Merger').
• At the effective time of the Merger (the 'Effective Time'), each share of Issuer common stock... was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to withholding taxes.
• At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00... became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.
• At the Effective Time, each Issuer stock option for which the applicable exercise price was equal to or greater than $13.00... was canceled for no consideration.

Industry Context

This filing reflects a consolidation event within the biotechnology or pharmaceutical sector, where a smaller company (Astria Therapeutics) is acquired by a larger entity (BioCryst Pharmaceuticals). Such mergers are common for strategic growth, pipeline expansion, or market share consolidation. It indicates a completed M&A transaction, shifting market dynamics for the involved companies.

Comparison to Industry Standards

• The merger consideration of both stock and cash is a common structure in pharmaceutical and biotech acquisitions, offering shareholders immediate liquidity and continued equity participation in the acquiring entity.
• The treatment of stock options, distinguishing between 'in-the-money' and 'out-of-the-money' options, is standard practice in M&A transactions to ensure fair value for vested options while eliminating unvested or underwater options.
• The 1-for-6 reverse stock split in 2021 by Astria Therapeutics prior to the merger suggests efforts to maintain listing requirements or improve stock perception, a common strategy for smaller biotech firms.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (Astria Therapeutics): Received a combination of BioCryst stock and cash for their shares, providing liquidity and continued exposure to the combined entity.
• Option Holders (Astria Therapeutics): In-the-money options were cashed out, while out-of-the-money options were canceled without consideration.
• Employees (Astria Therapeutics): Not explicitly detailed, but typically, mergers lead to integration and potential changes in employment for the acquired company's staff.
• Management (Astria Therapeutics): Directors like Jonathan Violin ceased their roles with the independent Astria Therapeutics.
• BioCryst Pharmaceuticals, Inc.: Expanded its portfolio and potentially market share through the acquisition.

Next Steps

• Former Astria Therapeutics shareholders will receive BioCryst common stock and cash as per the merger agreement.
• BioCryst Pharmaceuticals, Inc. will integrate Astria Therapeutics as a wholly-owned subsidiary.

Key Dates

Keywords

Astria Therapeutics, ATXS, BioCryst Pharmaceuticals, Merger, Form 4, Insider Trading, Stock Options, Corporate Action, Jonathan Violin, Acquisition